TY - JOUR
T1 - Insulin-like growth factor-1 (IGF-1) and glucose dysregulation in young adult patients with β-thalassemia major
T2 - causality or potential link?
AU - De Sanctis, Vincenzo
AU - Soliman, Ashraf
AU - Daar, Shahina
AU - Tzoulis, Ploutarchos
AU - Yassin, Mohamed A.
AU - Di Maio, Salvatore
AU - Kattamis, Christos
N1 - Publisher Copyright:
© Mattioli 1885.
PY - 2022/12/16
Y1 - 2022/12/16
N2 - Background: Insulin-like growth factor-1 (IGF-1) has been shown to lower blood glucose through stimulating glucose transport to fat and muscle and inhibiting hepatic glucose output. Although previous cross-sectional reports reported an association between low circulating concentrations of IGF-1 and glucose dysregulation (GD), its role is still debated. Aims of study: The present retrospective study was designed to assess the circulating IGF-1 levels in β-thalassemia major (β-TM) patients with normal oral glucose tolerance test (NGT-OGTT) and GD referred for an endocrine evaluation to explore the potential link between low IGF-1 and GD. Study design and methods: Our study included 34 young adult patients with β-TM; 12 patients with NGT after OGTT, 7 with impaired glucose tolerance (IGT), 9 with impaired fasting glucose (IFG) plus IGT, and 6 patients with β-TM-related diabetes mellitus (β-TM-DM). Results: Twenty-two β-TM patients with GD or β-TM-DM and 1 patient with NGT had IGF-1 levels below the 2.5th percentile. Correlation of IGF-1 with fasting plasma glucose, HOMA-IR (homeostatic model assessment for insulin resistance) and OGIS (oral glucose insulin sensitivity) was found. Moreover, a negative correlation was documented between ALT and the Insulinogenic Index (IGI) and a positive correlation between serum ferritin and PG 2-h after OGTT. Conclusion: This study reports for the first time an association between low levels of IGF-1 and GD in β-TM patients. Despite some limitations, our study can serve to generate proposals for more convenient and efficient methods to identify and treat early GD in patients with β-TM, and to conduct more extensive studies. (www.actabiomedica.it).
AB - Background: Insulin-like growth factor-1 (IGF-1) has been shown to lower blood glucose through stimulating glucose transport to fat and muscle and inhibiting hepatic glucose output. Although previous cross-sectional reports reported an association between low circulating concentrations of IGF-1 and glucose dysregulation (GD), its role is still debated. Aims of study: The present retrospective study was designed to assess the circulating IGF-1 levels in β-thalassemia major (β-TM) patients with normal oral glucose tolerance test (NGT-OGTT) and GD referred for an endocrine evaluation to explore the potential link between low IGF-1 and GD. Study design and methods: Our study included 34 young adult patients with β-TM; 12 patients with NGT after OGTT, 7 with impaired glucose tolerance (IGT), 9 with impaired fasting glucose (IFG) plus IGT, and 6 patients with β-TM-related diabetes mellitus (β-TM-DM). Results: Twenty-two β-TM patients with GD or β-TM-DM and 1 patient with NGT had IGF-1 levels below the 2.5th percentile. Correlation of IGF-1 with fasting plasma glucose, HOMA-IR (homeostatic model assessment for insulin resistance) and OGIS (oral glucose insulin sensitivity) was found. Moreover, a negative correlation was documented between ALT and the Insulinogenic Index (IGI) and a positive correlation between serum ferritin and PG 2-h after OGTT. Conclusion: This study reports for the first time an association between low levels of IGF-1 and GD in β-TM patients. Despite some limitations, our study can serve to generate proposals for more convenient and efficient methods to identify and treat early GD in patients with β-TM, and to conduct more extensive studies. (www.actabiomedica.it).
KW - glucose homeostasis
KW - Insulin-like growth factor-1
KW - oral glucose tolerance test
KW - β-thalassemia major
KW - Cross-Sectional Studies
KW - Humans
KW - Blood Glucose/metabolism
KW - Insulin-Like Growth Factor I
KW - Glucose
KW - Insulin
KW - beta-Thalassemia/complications
KW - Young Adult
KW - Glucose Intolerance/etiology
KW - Insulin Resistance/physiology
KW - Retrospective Studies
KW - Diabetes Mellitus, Type 2
UR - http://www.scopus.com/inward/record.url?scp=85144073960&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144073960&partnerID=8YFLogxK
UR - http://www.ncbi.nlm.nih.gov/pubmed/36533767
UR - https://www.mendeley.com/catalogue/254ce010-9208-3a4c-9e57-71540bb3f3d4/
U2 - 10.23750/abm.v93i6.13288
DO - 10.23750/abm.v93i6.13288
M3 - Article
C2 - 36533767
AN - SCOPUS:85144073960
SN - 0392-4203
VL - 93
SP - e2022331
JO - Acta Biomedica
JF - Acta Biomedica
IS - 6
M1 - e2022331
ER -